World’s First Single-Port Prostatectomy Using Titan Medical’s SPORT Surgical System Completed in a Preclinical Setting
February 06 2018 - 5:30PM
Titan Medical Inc. (“Titan” or the
“Company”) (TSX:TMD) (OTCQB:TITXF), a medical device
company focused on the design, development and commercialization of
a robotic surgical system for application in minimally invasive
surgery (“MIS”), reports the successful completion of a single-port
prostatectomy procedure using the SPORT Surgical System in a
preclinical setting. This procedure, conducted at the
Institute of Image-Guided Surgery at the Institut
Hospitalo-Universitaire de Strasbourg, France (“IHU Strasbourg”),
is part of the feasibility and validation studies intended to
support submissions to regulators in both the United States and
European Union.
David McNally, President and CEO of Titan
Medical, said, “We have conducted numerous feasibility studies at
our three centers of excellence in a variety of surgical
disciplines over the last four months. These studies, conducted on
procedures with varying degrees of complexity, have further
validated the promise of single-port robotic surgery. We are now
thrilled to report that we have demonstrated the successful
completion of a single-port prostatectomy using the SPORT system in
a preclinical setting. This is a particularly significant milestone
because multi-port robotic prostatectomy is today’s standard of
care. We are excited that under the expert guidance of Dr. Eric
Barret from Institut Mutualiste Montsouris in Paris we were able to
accomplish a complex urologic cancer procedure through a single
incision using the SPORT system.”
Eric Barret, M.D., a world-renowned robotic
urologic surgeon, said, “Prostatectomy is a highly complex and
advanced urologic procedure that many surgeons have now been able
to perform routinely with up to five ports using available robotic
technology. The ultimate goal must be to push the envelope further
and determine whether we can perform the same procedure through a
single incision around the umbilicus, thus creating a virtually
scar-less prostatectomy and potentially an outpatient fast-track
procedure. My experience with Titan Medical’s SPORT system in
attempting the first single-port prostatectomy was remarkable. I
was able to complete all of the critical tasks of a successful
prostate removal surgery through a single incision with sufficient
access and reach using the current instrument offering. This is
very encouraging.”
This procedure video and other preclinical
videos in urological, gynecological, general surgery and colorectal
surgical applications can be viewed on the Company’s website at
http://www.titanmedicalinc.com/technology/#videos.
About the Institute of
Image-Guided Surgery / IHU Strasbourg,
France
The Institute of Image-Guided Surgery is a
unique medical and surgical center dedicated to the management of
digestive diseases. It develops innovative surgery to deliver
personalized patient care, combining the most advanced minimally
invasive techniques and the latest medical imaging methods.
The Institute is:
- A healthcare center offering personalized treatment
using the least invasive techniques;
- A research center gathering teams to design and
develop instruments and procedures for the future;
- An international training center for professionals
and students driven to learn the most advanced minimally invasive
practices; and
- An innovation hub to foster technology transfer through
industrial partnerships and creation of startups.
The Institute is a designated part of the
“Programme Investissements d’Avenir” and benefits from the
financial support of the French government managed by the “Agence
Nationale de la Recherche.” The Institute is also funded by the
Région Grand Est, the Conseil Départemental du Bas-Rhin, the
Eurometropole de Strasbourg and the European Union.
For more information, please visit IHU
Strasbourg’s website at www.ihu-strasbourg.eu/ihu/en/.
About Titan Medical Inc.
Titan Medical Inc. is a Canadian public company
focused on research and development through to the planned
commercialization of computer-assisted robotic surgical
technologies for application in minimally invasive surgery. The
Company is currently developing the SPORT Surgical System, a
single-port robotic surgical system. The SPORT Surgical System is
comprised of a surgeon-controlled patient cart that includes a 3D
high definition vision system and multi-articulating instruments
for performing MIS procedures, and a surgeon workstation that
provides the surgeon with an advanced ergonomic interface to the
patient cart and a 3D endoscopic view inside the patient’s body
during MIS procedures. With the SPORT Surgical System, the Company
aims to pursue a broad set of surgical indications, including
general abdominal, gynecologic and urologic procedures.
For more information, please visit the Company’s
website at www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking
statements” which reflect the current expectations of management of
the Company’s future growth, results of operations, performance and
business prospects and opportunities. Wherever possible, words such
as “may”, “would”, “could”, “will”, “anticipate”, “believe”,
“plan”, “expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements. These statements reflect management’s current beliefs
with respect to future events and are based on information
currently available to management. Forward-looking statements
involve significant risks, uncertainties and assumptions. Many
factors could cause the Company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements, including, without limitation,
those listed in the “Risk Factors” section of the Company’s Annual
Information Form dated March 31, 2017 (which may be viewed at
www.sedar.com). Should one or more of these risks or uncertainties
materialize, or should assumptions underlying the forward-looking
statements prove incorrect, actual results, performance, or
achievements may vary materially from those expressed or implied by
the forward-looking statements contained in this news release.
These factors should be considered carefully, and prospective
investors should not place undue reliance on the forward-looking
statements. Although the forward-looking statements contained in
the news release are based upon what management currently believes
to be reasonable assumptions, the Company cannot assure current or
prospective investors that actual results, performance or
achievements will be consistent with these forward-looking
statements.
Contacts:
LHA Investor Relations Kim Sutton Golodetz(212)
838-3777kgolodetz@lhai.com orBruce Voss(310)
691-7100bvoss@lhai.com
Titan Medical (TSX:TMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Titan Medical (TSX:TMD)
Historical Stock Chart
From Apr 2023 to Apr 2024